Sinusitis is one of the most common chronic health problems in the United States, affecting approximately 37 million people each year. Those with chronic sinusitis typically suffer from a combination of headaches, congestion, facial pain/pressure, and other symptoms impacting their physical, functional and emotional quality of life.1
While chronic sinusitis is typically treated first with medication, at least 20 percent of people do not respond adequately to such treatment.2,3 In these cases, Balloon Sinuplasty technology – a safe and minimally-invasive alternative that widens the sinus openings – may be an option.4,5
The RELIEVA SCOUT® Multi-Sinus Dilation System features a flexible balloon that extends beyond its seeker-like tip for greater reach, enabling simple access to the Sphenoid, Frontal and Maxillary sinuses.
"Acclarent's new system includes the precision of flexible over-the-wire technology, with the versatility of a rail which can be shaped, creating a device that efficiently accesses and dilates multiple sinuses," said Dr. William Kane, Medical Director at Acclarent.
About Acclarent, Inc.
Acclarent, Inc., part of the Johnson & Johnson Family of Companies, is a medical device company located in Irvine, CA. Its singular focus is to free patients to live better lives by designing, developing and commercializing medical devices that address conditions affecting the ear, nose, and throat. For more than a decade, Acclarent has led the field in delivering innovative Balloon Sinuplasty technologies to ENT surgeons who manage patients with chronic sinusitis. For more information, visit www.acclarent.com.
Caution: Federal (U.S.) law restricts the sale, distribution or use of the RELIEVA SCOUT® Multi-Sinus Dilation System by or on the order of a physician.
For Physicians: Acclarent® Devices are intended for use by or under the direction of a physician who is trained in the use of Acclarent® Technology. Prior to use, it is important to read the Instructions for Use and to understand the contraindications, warnings, and precautions associated with these devices, as well as all products mentioned on this webpage.
For Patients: Acclarent® Technology is intended for use by or under the direction of a physician. Acclarent® Technology has associated risks, including tissue and mucosal trauma, infection, or possible optic injury. Consult your physician for a full discussion of risks and benefits to determine whether this procedure is right for you.
1 Benninger, M. Adult chronic rhinosinusitis: Definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003;129S:S1-S32.
2 Hessler J, Piccirillo J, et al. Clinical outcomes of chronic rhinosinusitis in response to medical therapy: Results of a prospective study. Am J Rhinol. 2007;21(1):10-18.
3 Lal D, Scianna J, et al. Efficacy of targeted medical therapy in chronic rhinosinusitis, and predictors of failure. Am J Rhinol Allergy. 23, 396-400, 2009.
4 Bolger WE, Brown CL, Church CA, et al. Safety and outcomes of balloon catheter sinusotomy: a multicenter 24-week analysis in 115 patients. Otolaryngol Head Neck Surg. 2007;137(1):10-20.
5 Weiss RL, Church CA, Kuhn FA, et al. Long-term outcome analysis of balloon catheter sinusotomy: two-year follow-up. Otolaryngol Head Neck Surg. 2008:139(3 Suppl 3):S38-46.
© Acclarent, Inc. 2016. All rights reserved.
Logo - http://photos.prnewswire.com/prnh/20160719/391265LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acclarent-announces-us-launch-of-relieva-scout-multi-sinus-dilation-system-300301169.html
SOURCE Acclarent, Inc.